

Hexafluoroacetone as a protecting and activating reagent: 5,5-difluoro- and *trans*-5-fluoropipeolic acids from glutamic acid

Alexander S. Golubev,^{a,b} Hartmut Schedel,^a Gabor Radics,^a Marco Fioroni,^{a,c}
Sven Thust^a and Klaus Burger^{a,*}

^aDepartment of Organic Chemistry, University of Leipzig, Johannisallee 29, D-04103 Leipzig, Germany

^bInstitute of Organoelement Compounds, Russian Academy of Sciences, Vavilov str. 28, GSP-1, V-334 Rus-117813 Moscow, Russia

^cDepartment of Chemistry, Technical University of Eindhoven, Helix Building, Eindhoven, The Netherlands

Received 14 November 2003; revised 5 December 2003; accepted 9 December 2003

Dedicated to Professor Dr. M. Lozinsky on the occasion of his 70th birthday

Abstract—Starting from hexafluoroacetone-protected (*S*)-glutamic acid, *trans*-5-fluoropipeolic and 5,5-difluoropipeolic acid have been synthesized. The piperidine ring was constructed by an intramolecular metal carbenoid NH insertion.
© 2003 Elsevier Ltd. All rights reserved.

The application of substituted pipeolic acids as building blocks in drug design is steadily growing.^{1,2} Furthermore, fluorine-containing proline³ and pipeolic acid derivatives⁴ represent valuable tools for the investigation of the *cis-trans* isomerization of the peptide bond⁵ and for the investigation of peptide and protein folding.⁶ Recently, we reported on the synthesis of 4-fluoro-substituted pipeolic acids.⁴ In an extension of our studies we now disclose a preparatively simple route to the virtually unknown 5-fluoro-substituted pipeolic acids.

Based on recently published results, we thought that a suitably protected 5-oxopipeolic acid could serve as a key precursor in the synthesis of 5-hydroxy-, 5,5-difluoro- and 5-fluoropipeolic acids. Concise synthetic approaches to enantiomerically pure 5-oxo-⁷ and 5-hydroxy-pipeolic⁸ acids starting from suitably protected glutamic acid derivatives have been described. Construction⁹ of the piperidine ring was achieved via ω -carboxy group activation and diazoketone formation, followed by a metal carbenoid NH insertion. This route attracted our interest, because it is preparatively simple, and both enantiomeric forms of glutamic acid are cheap and commercially available. We decided to combine the


advantages of this strategy^{7,8} with the advantages of the new hexafluoroacetone concept.

Glutamic acid **1** and hexafluoroacetone react at room temperature in DMSO or DMF to give 2,2-bis(trifluoromethyl)-1,3-oxazolidin-5-one **2**.¹⁰ In one-step, protection of the α -amino group and the adjacent carboxy group has been achieved, while the ω -carboxy group remains unaffected and can be derivatized regioselectively after separate activation.¹¹ When we tried to activate the ω -carboxy group of **2** by treatment with thionyl chloride we obtained the HFA-protected pGlu **3** in almost quantitative yield.¹² However, when milder activation strategies were applied, the intramolecular ring closure to give a lactam could be avoided. The mixed anhydride, formed on treatment of **2** with isobutyl chloroformate at -15°C in the presence of *N*-methyl morpholine, was reacted directly with an excess of diazomethane (>3 equiv) at 0°C to give diazoketone **4** in 61% yield (Scheme 1).


Compound **4** was subjected to a dirhodium tetraacetate catalyzed decomposition.¹³ The reaction proceeds via an electrophilic Fischer-type carbene complex, surprising the Wolff-type rearrangement completely in favour of an intramolecular metal carbenoid NH insertion.¹⁴ The best yields (70–80%)¹⁵ of the bicyclic compound **5** were obtained when a solution of **4** in chloroform was added dropwise to a vigorously stirred suspension of dirhodium tetraacetate in refluxing chloroform (Scheme 2).

Keywords: Glutamic acid; Hexafluoroacetone; Diazo ketones; Metal carbenoid NH insertion; DAST fluorination.


* Corresponding author. Tel.: +49-341-8622866; fax: +49-341-97365-99; e-mail: burger@organik.chemie.uni-leipzig.de



Scheme 1. Reagents and conditions: (a) hexafluoroacetone, DMSO; (b) SOCl₂; (c) ClOCO-*i*-Bu, *N*-methyl morpholine; (d) CH₂N₂.



Scheme 2. Reagents and conditions: (a) Rh₂(O₂CCH₃)₄, CHCl₃; (b) DAST in CH₂Cl₂; (c) aq HCl in dioxane; (d) propene oxide.



Scheme 3. Reagents and conditions: (a) BH₃·THF; (b) (CF₃SO₂)₂O; (c) 3HF·Et₃N, 3' MS (d) aq HCl in dioxane; (e) propene oxide.

Next, DAST (diethylaminosulfur trifluoride) fluorodeoxygenation¹⁶ of compound 5 was performed in solution in methylene chloride on adding 2 equiv of DAST at -78 °C to give the HFA-protected difluoropipeolic acid 6. Transformation of 6 into the unprotected 5,5-difluoro-L-pipeolic acid 7¹⁷ was achieved on stirring with aqueous HCl in dioxane (1:1) at room temperature followed by treatment with propene oxide to trap the HCl.

Reduction of the carbonyl group of 5 to give a hydroxy group was achieved on reaction with BH₃·THF at -78 °C¹⁸ with excellent regio- and stereo-selectivity in 92% yield. The reason for the high selectivity is the concave geometry of the bicyclic system,¹⁹ which favours *exo*-attack of the hydride ion to the carbonyl group to give exclusively the *cis*-hydroxy derivative 8 (Scheme 3).

Fluorodehydroxylation of 8 with DAST gave an inseparable mixture of compounds. Therefore, we transformed the hydroxy group into the triflate 9. The latter was converted into HFA-protected *trans*-fluoropipeolic acid 10 on treatment with 3HF·Et₃N in the presence of molecular sieves (3 Å)²⁰ in 60% yield.²¹ Transformation of 10 into the unprotected *trans*-5-fluoro-L-pipeolic acid 11 was achieved on stirring with HCl in dioxane

(1:1) at room temperature followed by treatment with propene oxide. Compounds 6 and 10 are carboxy-activated species and can be directly applied to peptide coupling.

Acknowledgements

This work was supported by Stiftung Volkswagenwerk, Hannover.

References and notes

1. (a) Partogyan-Halim, K.; Besson, L.; Aitken, D. J.; Husson, H.-P. *Eur. J. Org. Chem.* **2003**, 268–273; (b) Lloyd, R. C.; Smith, M. E. B.; Brick, D.; Taylor, S. J. C.; Chaplin, D. A.; McCague, R. *Org. Proc. Res. Dev.* **2002**, 6, 762–766; (c) Badorre, R.; Cativela, C.; Diaz-de-Villegas; Galvez, J. A. *Tetrahedron* **2002**, 58, 341–354; (d) Sata, N. U.; Kuwahara, R.; Murata, Y. *Tetrahedron Lett.* **2002**, 43, 115–118; (e) Greshok, T. J.; Funk, R. L. *J. Am. Chem. Soc.* **2002**, 124, 754–755; (f) Gillard, J.; Abraham, A.; Anderson, P. C.; Beaulieu, P. L.; Bogri, T.; Bousquet, Y.; Grenier, L.; Guse, I.; Lavallee, P. *J. Org. Chem.* **1996**, 61,

- 2226–2231; (g) Skiles, J. W.; Giannousis, P. P.; Fales, K. R. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 963–966.
2. (a) Letavic, M. A.; Axt, M. Z.; Barberia, J. T.; Carty, T. J.; Danley, D. E.; Geoghegan, K. F.; Halim, N. S.; Hoth, L. R.; Kamath, A. V.; Laird, E. R.; Lopresti-Morrow, L. L.; McClure, K. F.; Mitchell, P. G.; Natarajan, V.; Noe, M. C.; Pandit, J.; Reeves, L.; Schulte, G. K.; Snow, S. L.; Sweeney, F. J.; Tan, D. H.; Yu, C. H. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 1387–1390; (b) Lau, J. F.; Hansen, T. K.; Kilburn, J. P.; Frydenvang, K.; Holsworth, D. D.; Ge, Y.; Uyeda, R. T.; Judge, L. M.; Andersen, H. S. *Tetrahedron* **2002**, *58*, 7339–7344; (c) Cossy, J.; Belotti, D. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1989–1992; (d) Beaulieu, P. L.; Anderson, P. C.; Cameron, D. R.; Croteau, G.; Gorys, V.; Grand-Maitre, C.; Lamarre, D.; Liard, F.; Paris, W.; Plamondon, L.; Soucy, F.; Thibeault, D.; Wernic, D.; Yoakim, C.; Pav, S.; Tong, L. *J. Med. Chem.* **2000**, *43*, 1094–1108; (e) Ornstein, P. L.; Arnold, M. B.; Lunn, W. H. W.; Heinz, L. J.; Leander, J. D.; Lodge, D.; Schoepp, D. D. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 389–394; (f) Lamarre, D.; Croteau, G.; Bourgon, L.; Thibeault, D.; Wardrop, E.; Clouette, C.; Vaillancourt, M.; Cohen, E.; Pargelis, C.; Yoakim, C.; Anderson, P. C. *Antimicrob. Agents Chemother.* **1997**, *41*, 965–971.
 3. Burger, K.; Rudolph, M.; Fehn, S.; Sewald, N. *J. Fluorine Chem.* **1994**, *66*, 87–90.
 4. Golubev, A. S.; Schedel, H.; Radics, G.; Sieler, J.; Burger, K. *Tetrahedron Lett.* **2001**, *42*, 7941–7944.
 5. (a) Fischer, G. *Chem. Soc. Rev.* **2000**, *29*, 119–127; (b) Maison, W.; Lützen, A.; Kosten, M.; Schlemminger, I.; Westerhoff, O.; Saak, W.; Martens, J. *J. Chem. Soc., Perkin Trans. 1* **2000**, 1867–1871; (c) Wu, W.-J.; Raleigh, D. P. *J. Org. Chem.* **1998**, *63*, 6689–6698; (d) Kern, D.; Schutkowski, M.; Drakenberg, T. *J. Am. Chem. Soc.* **1997**, *119*, 8403–8408.
 6. (a) Renner, C.; Alefelder, S.; Bae, J. H.; Budisa, N.; Huber, R.; Moroder, L. *Angew. Chem.* **2001**, *113*, 949–951; (b) Eberhardt, E. S.; Panasik, N., Jr.; Raines, R. T. *J. Am. Chem. Soc.* **1996**, *118*, 12261–12266.
 7. (a) See Ref. 2a; (b) Adams, D. R.; Bailey, P. D.; Collier, I. D.; Heffernan, J. D.; Stokes, S. *J. Chem. Soc., Chem. Commun.* **1996**, 349–350; (c) Baldwin, J. E.; Adlington, R. M.; Godfrey, C. R. A.; Gollins, D. W.; Vaughan, J. G. *J. Chem. Soc., Chem. Commun.* **1993**, 1434–1435.
 8. (a) Marin, J.; Didierjean, C.; Aubry, A.; Briand, J.-P.; Guichard, G. *J. Org. Chem.* **2002**, *67*, 8440–8449; (b) Hoarau, S.; Fauchere, J. L.; Pappalardo, L.; Roumestant, M. L.; Viallefont, P. *Tetrahedron: Asymmetry* **1996**, *7*, 2585–2593; (c) Herdeis, C.; Heller, E. *Tetrahedron: Asymmetry* **1993**, *4*, 2085–2094; (d) Bailey, P. D.; Bryans, J. S. *Tetrahedron Lett.* **1988**, *29*, 2231–2234.
 9. (a) Davis, A. F.; Yang, B.; Deng, J. *J. Org. Chem.* **2003**, *68*, 5147–5152; (b) Burger, K.; Rudolph, M.; Fehn, S. *Angew. Chem., Int. Ed. Engl.* **1993**, *32*, 285–287.
 10. Weygand, F.; Burger, K.; Engelhardt, K. *Chem. Ber.* **1966**, *99*, 1461–1469.
 11. (a) Golubev, A. S.; Sewald, N.; Burger, K. *Tetrahedron* **1996**, *52*, 14757–14776; (b) Böttcher, C.; Burger, K. *Tetrahedron Lett.* **2003**, *44*, 4223–4226.
 12. Pumpor, K.; Böttcher, C.; Fehn, S.; Burger, K. *Heterocycles* **2003**, *61*, 259–269.
 13. Ko, K.-Y.; Lee, K.-I.; Kim, W.-J. *Tetrahedron Lett.* **1992**, *33*, 6651–6652.
 14. (a) Doyle, M. P. *Chem. Rev.* **1986**, *86*, 919–939; (b) Doyle, M. P.; Mc Kervey, M. A.; Ye, T. *Modern Catalytic Methods for Organic Synthesis with Diazo Compounds. From Cyclopropanes to Ylides*; Wiley: New York, 1998.
 15. Compound **6**: colourless crystals; mp 34–35 °C; $[\alpha]_D^{22} = -14.9$ (*c* 1, CH_2Cl_2); IR (KBr): ν 1842 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3): δ 1.84 (1H, br m, CH_2CHN), 1.90 (1H, m, $\text{CH}_2\text{CH}_2\text{CHN}$), 2.20 (1H, br m, CH_2CHN), 2.41 (1H, m, $\text{CH}_2\text{CH}_2\text{CHN}$), 3.11 (1H, br dd, $^3J_{\text{HF}} = 26.1$ Hz, $^2J = 12.4$ Hz, CH_2N), 3.62 (1H, br d, $^3J = 10.5$ Hz, CHN), 3.68 (1H, br t, $J_{\text{HF},\text{HH}} = 11.6$ Hz, CH_2N); ^{13}C NMR (151 MHz, CDCl_3): δ 23.75 (d, $^3J_{\text{CF}} = 10.3$ Hz, CH_2CHN), 31.81 (dd, $^2J_{\text{CF}} = 25.9$ Hz, $^2J_{\text{CF}} = 23.9$ Hz, $\text{CH}_2\text{CH}_2\text{CHN}$), 50.77 (dd, $^2J_{\text{CF}} = 38.8$ Hz, $^2J_{\text{CF}} = 27.1$ Hz, CH_2N), 55.14 (CHN), 88.06 (dqq, $^2J_{\text{CF}} = 34.4$ Hz, $^2J_{\text{CF}} = 32.4$ Hz, $^4J_{\text{CF}} = 2.0$ Hz, $\text{C}(\text{CF}_3)_2$), 117.62 (ddq, $^1J_{\text{CF}} = 247.9$ Hz, $^1J_{\text{CF}} = 241.9$ Hz, $^5J_{\text{CF}} = 1$ Hz, CF_2), 120.20 (qq, $^1J_{\text{CF}} = 287.1$ Hz, $^3J_{\text{CF}} = 1$ Hz, CF_3), 121.65 (q, $^1J_{\text{CF}} = 293.7$ Hz, CF_3), 166.90 (d, $^5J_{\text{CF}} = 1.8$ Hz, $\text{C}=\text{O}$); ^{19}F NMR (376 MHz, CDCl_3 without ^1H decoupling): δ –75.62 (q, $^4J_{\text{FF}} = 8.4$ Hz, CF_3), –78.73 (dq, $^4J_{\text{FF}} = 8.4$ Hz, $^6J_{\text{FF}} = 1.2$ Hz, CF_3), –102.86 (d, $^2J_{\text{FF}} = 244.6$ Hz, CF_2), –104.40 (dq, $^2J_{\text{FF}} = 244.6$ Hz, $^6J_{\text{FF}} = 1.2$ Hz, CF_2); MS (EI) *m/z* (%): 313 [M]⁺ (6), 266 (9), 244 (20), 216 (100), 196 (13), 176 (7), 100 (10), 69 (20).
 16. (a) Hudlicky, M. *Org. React.* **1988**, *34*, 513–637; (b) *Chemistry of Organic Fluorine Compounds*; Hudlicky, M., Pavlath, A. E., Eds.; *ACS Monograph 187*; American Chemical Society: Washington, DC, 1995; pp 240–242, and references cited therein.
 17. 5,5-Difluoro-(S)-pipecolic acid **7**: white powder; mp 250 °C (sealed tube); $[\alpha]_D^{22} = -9$ (*c* 1, H_2O); ^1H NMR (300 MHz, D_2O): δ 1.85–2.32 (m, 4H), 3.38 (ddd, $J = 23.5$, 13.5, 5.5 Hz, 1H), 3.58 (m, 1H), 3.72 (dd, $J = 10.7$, 2.8 Hz, 1H); ^{13}C NMR (50.3 MHz, D_2O): δ 25.30 (t, $J = 5$ Hz), 32.38 (t, $J = 23$ Hz), 48.55 (t, $J = 32$ Hz), 59.86, 120.92 (t, $J = 242$ Hz), 174.88 (t, $J = 5$ Hz).
 18. Zajlewicz, M.; Brown, H. C. In *Encyclopedia of Reagents for Organic Synthesis*; Paquette, L. A., Ed.; Wiley: Chichester, 1995; pp 638–644.
 19. (a) Fehn, S.; Burger, K. *Tetrahedron: Asymmetry* **1997**, *8*, 2001–2004; (b) See Ref. 9b.
 20. Dmowski, W. Replacement of Oxygen by Fluorine. In *Chemistry of Organic Fluorine Compounds II, A Critical Review*; Hudlicky, M., Pavlath, A. E., Eds.; *ACS Monograph 187*; American Chemical Society: Washington, DC, 1995; p 213.
 21. Compound **10**: colourless crystals; mp 51 °C, $[\alpha]_D^{22} = -9$ (*c* 1, CHCl_3); ^1H NMR (600 MHz, CDCl_3): δ 1.62 (1H, m, $\text{CH}_2\text{CH}_2\text{CHN}$), 1.92 (1H, m, CH_2CHN), 2.04 (1H, m, CH_2CHN), 2.33 (1H, m, $\text{CH}_2\text{CH}_2\text{CHN}$), 3.03 (1H, br dd, $J = 13.4$ Hz, $J_{\text{HF}} = 35.5$ Hz, CH_2N), 3.54 (1H, br d, $J = 11.5$ Hz, CHN), 3.72 (1H, br t, $J = 12.7$ Hz, CH_2N), 4.78 (1H, br d, $J_{\text{HF}} = 45.9$ Hz, CHF); ^{13}C NMR (151 MHz, CDCl_3): δ 22.02 (CH_2CHN), 28.18 (d, $^2J_{\text{CF}} = 22.2$ Hz, $\text{CH}_2\text{CH}_2\text{CHN}$), 49.02 (d, $^2J_{\text{CF}} = 20.8$ Hz, CH_2N), 55.55 (CHN), 83.65 (d, $^1J_{\text{CF}} = 179.2$ Hz, CHF), 88.78 (qq, $^2J_{\text{CF}} = 33.5$ Hz, $^2J_{\text{CF}} = 31.3$ Hz, $\text{C}(\text{CF}_3)_2$), 120.28 (qq, $^1J_{\text{CF}} = 287.1$ Hz, CF_3), 121.83 (q, $^1J_{\text{CF}} = 294.2$ Hz, CF_3), 168.27 ($\text{C}=\text{O}$); ^{19}F NMR (376 MHz, CDCl_3 without ^1H decoupling): δ –75.28 (br q, $^4J_{\text{FF}} = 8$ Hz, CF_3), –78.68 (br dq, $^4J_{\text{FF}} = 8.4$ Hz, $^6J_{\text{FF}} = 1.3$ Hz, CF_3), –187.24 (br dtq, $^2J_{\text{HF}} = 45.3$ Hz, $^3J_{\text{HF}} = 34.3$ Hz, $^3J_{\text{HF}} = 11.0$ Hz, $^6J_{\text{FF}} = 1.3$ Hz, CHF); MS (EI) *m/z* (%): 295 (7) [M]⁺, 198 (25) [M– CF_3CO]⁺, 169 (15), 149 (14), 102 (82), 82 (36), 69 (62).